Cibus Inc. has released its first quarter financial results for 2025, reporting a net loss per share of Class A common stock of $1.34, an increase from the $1.12 net loss per share reported in the same period last year. This increase of $0.22 is primarily attributed to a non-cash goodwill impairment in the first quarter, which contributed approximately $0.57 to the net loss per share. The company's cash and cash equivalents as of March 31, 2025, stood at $23.6 million. Cibus expects this existing cash position to be sufficient to cover operating expenses and capital expenditure requirements into the third quarter of 2025, considering implemented cost-saving measures. Research and development expenses saw a slight decrease, totaling $11.8 million compared to $12.0 million in the same quarter of the previous year, primarily due to cost reduction initiatives. In terms of business developments, Cibus continues to advance its rice business, with significant momentum building around its first stacked gene-edited herbicide tolerance traits, HT1 and HT3. The company targets a commercial launch of these traits by 2027, with customer germplasm integration underway in multiple markets. Additionally, Cibus has received a positive regulatory decision in Ecuador, where the Ministry of Agriculture and Livestock determined that the HT1 and HT3 rice traits are equivalent to those developed through conventional breeding methods. The company's disease resistance program is also making progress, with positive data for multiple modes of action against Sclerotinia in Canola, drawing considerable commercial interest.